CD274 and non-small cell lung carcinoma: In subgroup analyses, patients with cStage IIIA NSCLC (hazard ratio: 0.54, 95% CI 0.37–0.80) or those with high PD-L1 expression (TPS 50% or higher, hazard ratio: 0.24, 95% CI 0.10–0.61) showed better EFS with the addition of nivolumab, while the impact of the addition of nivolumab was not so high in the counterpart subgroups (patients with cStage IB–II NSCLC, hazard ratio: 0.87, 95% CI 0.48–1.56, and those with negative PD-L1 expression, hazard ratio: 0.85, 95% CI 0.54–1.32) (Table 3).